Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Inclusion Criteria:

1. Male or female, aged 18-75 years old;
2. Head and neck tumors confirmed by histology or cytology (including oral cancer,oropharyngeal cancer, hypopharyngeal cancer, and laryngeal cancer);
3. Receive radical synchronous radiotherapy and chemotherapy;
4. The Eastern Oncology Collaborative Group (ECOG) physical fitness score of the subjectswas ≤ 2 points;
5. Adequate organ and bone marrow function;
6. The expected life is at least 12 weeks;
7. Pregnant or fertile patients (male or female) use reliable contraceptive measures;
8. When screening female patients with potential pregnancy, the pregnancy test must benegative;
9. The subjects voluntarily and strictly comply with the requirements of the researchprotocol and sign a written informed consent form.

Exclusion Criteria:

1. Recurrent and metastatic head and neck tumors;
2. Previously underwent tumor resection surgery for treatment;
3. Patients with platinum drug intolerance;
4. Receiving any known or potential antiemetic medication within 24 hours prior to thefirst day, or experiencing symptoms of vomiting, retching, or mild nausea within 24hours prior to the first day;
5. Take NK1（neurokinin-1） receptor antagonists or any study medication within 4 weeksbefore the start of the experiment;
6. Use CYP3A4 inducer within 4 weeks before chemotherapy, and use CYP3A4 substrate orstrong or moderate CYP3A4 inhibitor within 1 week;
7. Serious cardiovascular, pulmonary, diabetes, mental and other diseases;
8. Pregnant or lactating women, patients with fertility who are unwilling or unable totake effective contraceptive measures;
9. Drug and/or alcohol abuse;
10. Hypocalcemia or any other condition that may cause vomiting;
11. There are significant factors that affect the absorption of oral medication, such aschronic diarrhea and intestinal obstruction;
12. The subject has allergic reactions to Netopitam Palonosetron capsules or any of theirexcipients;
13. Within 30 days prior to the baseline visit, the subject participated in anotherclinical study and used any exploratory drugs or devices; Allow participation inobservational research;
14. The researcher determines other situations that may affect the progress of clinicalresearch and the determination of research results.